AstraZeneca awarded approval for latest diabetes drug
22nd Jan 2014 08:07
AstraZeneca and its partner Bristol-Myers Squibb have been granted marketing authorisation by the European Commission for Xigduo, its treatment of type 2 diabetes in the European Union. It is the first regulatory approval for a fixed dose combination treatment of its kind. The product is for use
Read moreLondon pre-open: FTSE to float higher ahead of BoE minutes
22nd Jan 2014 07:21
City sources predict the FTSE 100 will open 18 points above yesterday's close of 6,834.26, ahead of the release of the most recent Bank of England (BoE) minutes and the release of UK unemployment figures. In the US last night markets finished in a mixed fashion, with the gains on the Nasdaq and S&
Read moreFriday broker round-up UPDATE
17th Jan 2014 10:05
Aberdeen Asset Management: JP Morgan cuts target price from 544p to 529p, while its overweight rating remains unchanged. Canaccord Genuity reduces target price from 586p to 540p and reiterates a buy recommendation. UBS lowers target price from 540p to 520p and keeps a buy recommendation. Ashtead Gr
Read moreThursday broker round-up UPDATE
16th Jan 2014 08:59
Aberdeen Asset Management: Canaccord Genuity cuts target price from 586p to 540p, while its buy recommendation remains unchanged. Anglo American: UBS ups target price from 1500p to 1580p upgrading from neutral to buy. Antofagasta: Investec reduces target price from 716p to 685p maintaining a sell
Read moreWednesday broker round-up UPDATE
15th Jan 2014 08:42
African Barrick Gold: Liberum Capital downgrades to sell with a target price of 147p. Deutsche Bank lowers target price from 190p to 180p, while maintaining a hold recommendation. African Minerals: Deutsche Bank shifts target price from 410p to 414p and maintains a buy recommendation. Amlin: JP Mo
Read moreLondon close: BSkyB leads markets higher after decent economic data
14th Jan 2014 16:31
- Markets at highest level since October 30th - UK inflation falls to BoE target - Eurozone industrial production, US retail sales beat forecasts - UBS highlights potential M&A at BSkyB techMARK 2,818.48 +0.54% FTSE 100 6,766.86 +0.14% FTSE 250 16,236.02 -0.12% Markets managed to finish in positiv
Read moreSector movers: AstraZeneca, Shire lift pharma stocks on upbeat guidance
14th Jan 2014 15:22
Decent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks. At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts c
Read moreFTSE 100 movers: Sky lifted by broker comments
14th Jan 2014 15:07
UBS upgraded BSkyB to 'buy' this morning, giving the stock a decent lift as it said that competitive concerns have been priced in and growth opportunities are now being overlooked at the broadband and pay-TV group. It also sees M&A upside in the stock, speculating about a possible merger by Fox to c
Read moreLondon midday: Stocks lower but losses trimmed as inflation eases
14th Jan 2014 11:20
- CPI inflation falls to BoE target - US earnings season in focus - UBS sees merger opportunities at BSkyB - Ashmore reports fall in AuM techMARK 2,800.75 -0.09% FTSE 100 6,740.89 -0.24% FTSE 250 16,152.84 -0.63% Nervousness ahead of the US earnings season and a disappointing update from fund mana
Read moreLondon open: Markets pull back from 10-week high, Ashmore drops
14th Jan 2014 08:35
- Ashmore reports fall in AuM, drags peers lower - Lockhart quashes stimulus optimism - FTSE 100 pulls back from 10-week high techMARK 2,798.85 -0.16% FTSE 100 6,723.86 -0.49% FTSE 250 16,144.85 -0.68% A disappointing set of results from Ashmore and a host of other stocks on the FTSE 350 dampened
Read moreAstraZeneca foresees sooner-than-expected return to growth
14th Jan 2014 07:09
Biopharmaceutical giant AstraZeneca has said it expects to return to growth sooner than analysts currently predict. Chief Executive Officer Pascal Soriot said that the company has made good progress in accelerating and replenishing its portfolio in its three core therapeutic areas of oncology, card
Read moreLondon pre-open: FTSE to slump at opening bell
14th Jan 2014 07:02
- Drop of 37 points expected early on - S&P 500 registers worst performance in two months - Focus on UK inflation City sources predict the FTSE 100 will open 37 points below yesterday's close of 6,757.15, tracking declines seen in the US overnight, which saw the S&P 500 register its poorest perform
Read moreLondon pre-open: FTSE to begin week with a slow start
13th Jan 2014 07:29
City sources predict the FTSE 100 will open 13 points higher than Friday's close of 6,739.94, as investors weigh up last week's US jobs data and a mixed performance by Asia stocks overnight. According to Craig Erlam from Alpari, the fact stocks are set to move higher early on "suggests that we're
Read moreAstraZeneca's diabetes drug Farxiga approved by FDA
13th Jan 2014 07:08
AstraZeneca's diabetes drug Farxiga has been approved by the US Food and Drug Administration. The drug, which AstraZeneca developed with Bristol-Myers Squibb Company, is a once-daily oral treatment to improve glycaemic control in adults with type 2 diabetes mellitus. The drug can be taken with or
Read moreAstraZeneca gets US FDA approval for Farxiga diabetes drug
9th Jan 2014 08:00
Drug-maker AstraZeneca was given a boost as a diabetes treatment was given the green light by the US regulator. Broker JPMorgan Cazenove has forecast a $600m peak in-market potential in the US for the treatment, though admitted this could prove conservative, with Morningstar analyst Damien Conover
Read more